The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Outcome of Children With Metastatic Medulloblastoma Treated With Carboplatin During Craniospinal Radiotherapy: A Children's Oncology Group Phase I/II Study
Open accessAbstract
Purpose: We evaluated the feasibility of administering carboplatin as a radiosensitizer during craniospinal radiation therapy (CSRT) to patients with high-risk medulloblastomas (MBs) and supratentorial primitive neuroectodermal tumors, and we report the outcome in the subset with metastatic (M+) MB. Patients and Methods: After surgery, patients received 36 Gy CSRT with boosts to sites of disease. During radiation, patients received 15 to 30 doses of carboplatin (30-45 mg/m 2 /dose), along with vincristine (VCR) once per week for 6 weeks. Patients on regimen A received 6 months of maintenance chemotherapy (MC) with cyclophosphamide and VCR. Once the recommended phase II dose (RP2D) of carboplatin was determined, cisplatin was added to the MC (regimen B). Results: In all, 161 eligible patients (median age, 8.7 years; range, 3.1 to 21.6 years) were enrolled. Myelosuppression was dose limiting and 35 mg/m 2 /dose × 30 was determined to be the RP2D of carboplatin. Twenty-nine (36%) of 81 patients with M+ MB had diffuse anaplasia. Four patients were taken off study within 11 months of completing radiotherapy for presumed metastatic progression and are long-term survivors following palliative chemotherapy. Excluding these four patients, 5-year overall survival ± SE and progression-free survival ± SE for M+ patients treated at the RP2D on regimen A was 82% ± 9% and 71% ± 11% versus 68% ± 10% and 59% ± 10% on regimen B (P = .36). There was no difference in survival by M stage. Anaplasia was a negative predictor of outcome. Conclusion: The use of carboplatin as a radiosensitizer is a promising strategy for patients with M+ MB. Early progression should be confirmed by biopsy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ellison, D. W., Kocak, M., Dalton, J., Megahed, H., Lusher, M. E., Ryan, S. L., Zhao, W., Nicholson, S. L., Taylor, R. E., Bailey, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.2810 · Cited by 302
Cited by
Northcott, P. A., Robinson, G. W., Kratz, C. P., Mabbott, D. J., Pomeroy, S. L., Clifford, S. C., Rutkowski, S., Ellison, D. W., Malkin, D., Taylor, M. D., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0063-6 · Cited by 649
Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma
Zhukova, N., Ramaswamy, V., Remke, M., Pfaff, E., Shih, D. J. H., Martin, D. C., Castelo-Branco, P., Baskin, B., Ray, P. N., Bouffet, E., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.5052 · Cited by 485
Self-citationYock, T. I., Yeap, B. Y., Ebb, D. H., Weyman, E., Eaton, B. R., Sherry, N. A., Jones, R. M., MacDonald, S. M., Pulsifer, M. B., Lavally, B., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00167-9 · Cited by 350
Self-citationJuraschka, K., & Taylor, M. D. (2019) · Journal of Neurosurgery: Pediatrics · doi:10.3171/2019.5.peds18381 · Cited by 275
Gajjar, A., Robinson, G. W., Smith, K. S., Lin, T., Merchant, T. E., Chintagumpala, M., Mahajan, A., Su, J., Bouffet, E., Bartels, U., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01372 · Cited by 241
Metadata
- Authors
- Jakacki, R. I., Burger, P. C., Zhou, T., Holmes, E. J., Kocak, M., Onar, A., Goldwein, J., Mehta, M., Packer, R. J., Tarbell, N., Fitz, C., Vezina, G., Hilden, J., & Pollack, I. F.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-07-20
- Volume
- 30
- Issue
- 21
- Pages
- 2648-2653
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2160607660
- Cited by
- 217
- References
- 1
- FWCI
- 6.38
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Outcome of Children With Metastatic Medulloblastoma Treated With Carboplatin During Craniospinal Radiotherapy: A Children's Oncology Group Phase I/II Study. https://app.cochat.ai/papers/10.1200/jco.2011.40.2792
- The paper
- Jakacki, R. I., Burger, P. C., Zhou, T., Holmes, E. J., Kocak, M., Onar, A., Goldwein, J., Mehta, M., Packer, R. J., Tarbell, N., Fitz, C., Vezina, G., Hilden, J., & Pollack, I. F. (2012). Outcome of Children With Metastatic Medulloblastoma Treated With Carboplatin During Craniospinal Radiotherapy: A Children's Oncology Group Phase I/II Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2011.40.2792
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.